达拉图穆马
医学
自体干细胞移植
免疫疗法
肿瘤科
移植
多发性骨髓瘤
干细胞
内科学
免疫学
癌症
硼替佐米
生物
遗传学
作者
Serena Rocchi,Beatrice Anna Zannetti,Giovanni Marconi,Francesco Lanza
出处
期刊:Cells
[MDPI AG]
日期:2024-05-16
卷期号:13 (10): 853-853
被引量:1
标识
DOI:10.3390/cells13100853
摘要
Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has established itself as a core treatment for newly diagnosed multiple myeloma (NDMM) patients in the past 30 years. Induction therapy, HDM-ASCT, and subsequent consolidation and maintenance therapy comprise the current fundamental framework for MM treatment. The introduction of anti-CD38 monoclonal antibodies such as daratumumab and isatuximab has changed the treatment paradigm for transplant-eligible NDMM patients in that quadruplets have become the new standard induction therapy. The treatment landscape of MM is undergoing a transformative shift with the introduction of potent new immunotherapies, such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), which are currently used in the relapsed/refractory setting (RRMM) and are already being tested in the NDMM. This review will focus on the incorporation of immunotherapy in the treatment scenario of NDMM patients eligible for ASCT.
科研通智能强力驱动
Strongly Powered by AbleSci AI